Amedisys, Inc. (NASDAQ:AMED) Expected to Post Q3 2023 Earnings of $1.45 Per Share

Amedisys, Inc. (NASDAQ:AMEDGet Rating) – Stock analysts at SVB Leerink dropped their Q3 2023 earnings per share (EPS) estimates for Amedisys in a research report issued on Monday, June 20th. SVB Leerink analyst W. Mayo now anticipates that the health services provider will post earnings per share of $1.45 for the quarter, down from their prior estimate of $1.57. SVB Leerink has a “Market Perform” rating and a $107.00 price objective on the stock. The consensus estimate for Amedisys’ current full-year earnings is $5.29 per share. SVB Leerink also issued estimates for Amedisys’ Q4 2023 earnings at $1.48 EPS.

AMED has been the subject of a number of other research reports. Oppenheimer reissued an “outperform” rating and issued a $200.00 target price on shares of Amedisys in a report on Friday, April 29th. Jefferies Financial Group restated a “buy” rating and issued a $200.00 price target on shares of Amedisys in a research report on Thursday, April 7th. BMO Capital Markets upgraded Amedisys from a “market perform” rating to an “outperform” rating and dropped their price target for the company from $210.00 to $190.00 in a research report on Friday, February 25th. UBS Group upgraded Amedisys from a “sell” rating to a “neutral” rating and raised their price target for the company from $152.00 to $168.00 in a research report on Tuesday, March 1st. Finally, Raymond James dropped their price target on Amedisys from $200.00 to $180.00 in a research report on Friday, April 29th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and ten have issued a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $173.27.

Amedisys stock opened at $115.28 on Wednesday. Amedisys has a one year low of $101.61 and a one year high of $276.21. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.03 and a current ratio of 1.03. The business has a fifty day moving average of $122.52 and a two-hundred day moving average of $142.33. The company has a market cap of $3.76 billion, a P/E ratio of 19.84, a price-to-earnings-growth ratio of 2.10 and a beta of 0.89.

Amedisys (NASDAQ:AMEDGet Rating) last released its earnings results on Wednesday, April 27th. The health services provider reported $1.23 EPS for the quarter, beating analysts’ consensus estimates of $1.11 by $0.12. Amedisys had a return on equity of 19.37% and a net margin of 8.59%. The company had revenue of $545.26 million during the quarter, compared to the consensus estimate of $557.81 million. During the same quarter last year, the company earned $1.54 earnings per share.

In other Amedisys news, insider David L. Kemmerly sold 2,500 shares of Amedisys stock in a transaction dated Tuesday, March 29th. The stock was sold at an average price of $177.31, for a total value of $443,275.00. Following the completion of the sale, the insider now owns 16,336 shares in the company, valued at approximately $2,896,536.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 2.10% of the stock is owned by insiders.

A number of institutional investors and hedge funds have recently bought and sold shares of AMED. Riverbridge Partners LLC grew its holdings in Amedisys by 57.0% in the 4th quarter. Riverbridge Partners LLC now owns 1,588,750 shares of the health services provider’s stock valued at $257,187,000 after buying an additional 576,633 shares during the period. Mackenzie Financial Corp lifted its stake in shares of Amedisys by 39,235.8% in the 4th quarter. Mackenzie Financial Corp now owns 570,369 shares of the health services provider’s stock valued at $92,331,000 after purchasing an additional 568,919 shares in the last quarter. Allspring Global Investments Holdings LLC acquired a new position in shares of Amedisys in the 4th quarter valued at about $85,286,000. JPMorgan Chase & Co. lifted its stake in shares of Amedisys by 23.5% in the 1st quarter. JPMorgan Chase & Co. now owns 1,384,041 shares of the health services provider’s stock valued at $238,457,000 after purchasing an additional 263,275 shares in the last quarter. Finally, Bellevue Group AG lifted its stake in shares of Amedisys by 61.8% in the 4th quarter. Bellevue Group AG now owns 490,012 shares of the health services provider’s stock valued at $79,323,000 after purchasing an additional 187,214 shares in the last quarter. Institutional investors own 90.47% of the company’s stock.

About Amedisys (Get Rating)

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, Personal Care, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.

Recommended Stories

Earnings History and Estimates for Amedisys (NASDAQ:AMED)

Receive News & Ratings for Amedisys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amedisys and related companies with MarketBeat.com's FREE daily email newsletter.